Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
A phase 3 trial of Gedatolisib, Palbociclib, Fulvestrant and Alpelisib in advanced solid tumours, run by Celcuity Inc, active and no longer recruiting.
Overview
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) is a phase 3 interventional study registered as NCT05501886 by Celcuity Inc, with 701 participants enrolled, started 2022-12-08 and due to reach its primary completion in 2026-06-30. Interventions recorded: Gedatolisib, Palbociclib, Fulvestrant and Alpelisib.
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Shares Celcuity, Gedatolisib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Palbociclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Shares Alpelisib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares Alpelisib, Fulvestrant and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Palbociclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.